Abstract: The current invention relates to fusion proteins comprising at least one functional periplasmic binding protein, at least one labeling moiety and at least one fluorescent protein. In one embodiment, the periplasmic binding protein is a functional glucose-galactose binding protein (GGBP). The invention also relates to methods for quantifying an analyte, for example glucose, in a cell or tissue comprising administering a composition comprising a fluorescent periplasmic binding fusion protein portion to the cell or tissue, and measuring the fluorescence of the fluorescent periplasmic binding fusion protein.

Abstract: The invention is directed to compositions of mutated binding proteins containing reporter groups, analyte biosensor devices derived therefrom, and their use as analyte biosensors both in vitro and in vivo.

Abstract: Reactive fluorescent dyes compositions and methods of using same are disclosed. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed having thiol-reactive groups. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed that exhibit a fluorescence emission of at least about 575 nm. Biosensors are disclosed having a binding protein and a squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus.

Abstract: The invention is directed to compositions of mutated binding proteins containing thiol groups for coupling to sensor surfaces, analyte biosensor devices derived there from, and methods of their use as analyte biosensors both in vitro and in vivo.

Abstract: The invention is directed to compositions of mutated binding proteins containing thiol groups for coupling to sensor surfaces, analyte biosensor devices derived there from, and methods of their use as analyte biosensors both in vitro and in vivo.

Abstract: The invention is directed to binding proteins, proteins comprising reporter groups, compositions of binding molecules comprising reporter groups in analyte permeable matrices, and their use as analyte biosensors both in vitro and in vivo.

Abstract: The current invention relates to fusion proteins comprising at least one functional periplasmic binding protein, at least one labeling moiety and at least one fluorescent protein. In one embodiment, the periplasmic binding protein is a functional glucose-galactose binding protein (GGBP). The invention also relates to methods for quantifying an analyte, for example glucose, in a cell or tissue comprising administering a composition comprising a fluorescent periplasmic binding fusion protein portion to the cell or tissue, and measuring the fluorescence of the fluorescent periplasmic binding fusion protein.

Abstract: A device for sensing analyte concentration, and in particular glucose concentration, in vivo or in vitro is disclosed. An optical conduit, preferably an optical fiber has an optical system at the proximal end of the optical conduit. A sensing element is attached to the distal end of the optical conduit, and comprises at least one binding protein adapted to bind with at least one target analyte. The sensing element further comprises at least one reporter group that undergoes a luminescence change with changing analyte concentrations. Optionally, the sensing element includes reference groups with luminescence properties that are substantially unchanged by variations in the analyte concentrations.

Abstract: The invention is directed to entrapped mutated binding proteins, mutated binding proteins containing reporter groups, compositions of mutated binding proteins containing reporter groups in analyte permeable matrixes, and their use as analyte biosensors both in vitro and in vivo

Abstract: The invention is directed to compositions of mutated binding proteins containing reporter groups, analyte biosensor devices derived therefrom, and their use as analyte biosensors both in vitro and in vivo.